Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Leases (2019 - 2025)

Guided Therapeutics' Current Leases history spans 7 years, with the latest figure at $45000.0 for Q4 2025.

  • On a quarterly basis, Current Leases fell 57.55% to $45000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $45000.0, a 57.55% decrease, with the full-year FY2025 number at $45000.0, down 57.55% from a year prior.
  • Current Leases hit $45000.0 in Q4 2025 for Guided Therapeutics, down from $76000.0 in the prior quarter.
  • Over the last five years, Current Leases for GTHP hit a ceiling of $110000.0 in Q1 2025 and a floor of $42000.0 in Q1 2021.
  • Historically, Current Leases has averaged $80800.0 across 5 years, with a median of $80500.0 in 2022.
  • Biggest five-year swings in Current Leases: crashed 57.58% in 2021 and later skyrocketed 66.67% in 2022.
  • Tracing GTHP's Current Leases over 5 years: stood at $67000.0 in 2021, then rose by 17.91% to $79000.0 in 2022, then increased by 15.19% to $91000.0 in 2023, then rose by 16.48% to $106000.0 in 2024, then tumbled by 57.55% to $45000.0 in 2025.
  • Business Quant data shows Current Leases for GTHP at $45000.0 in Q4 2025, $76000.0 in Q3 2025, and $104000.0 in Q2 2025.